This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04910/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04910/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04910/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04910/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB04910/identifier/wikipedia/

Statements

Subject Item
n2:DB04910
rdf:type
n3:Drug
n3:description
Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
n3:generalReferences
# Gokbulut C, Nolan AM, McKellar QA: Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. Res Vet Sci. 2002 Feb;72(1):11-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12002632 # Magambo JK: Ultrastructural changes in Ascaris suum after oxibendazole treatment. Afr J Health Sci. 1998 Feb;5(1):38-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17580993
n3:group
investigational
n3:indication
Investigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications.
owl:sameAs
n12:DB04910
dcterms:title
Oxibendazole
adms:identifier
n6:4461 n7:10486937 n8:Oxibendazole n9:DB04910 n10:4622
n3:mechanismOfAction
Oxibendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
n3:synonym
Oxibendazolo Methyl (5-propoxy-1H-benzimidazol-2-yl)carbamate Oxybendazole OBZ (5-Propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester methyl 5-[n-propoxy]benzimidazole-2-carbamate Oxibendazolum 5-Propoxy-2-benzimidazolecarbamic acid methyl ester Methyl 5-n-propoxy-2-benzimidazole carbamate Methyl 5-propoxy-2-benzimidazolecarbamate
n3:IUPAC-Name
n4:271B5EA0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5EA6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5EA5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5EA2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5EA3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5EA4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E9E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E9F-363D-11E5-9242-09173F13E4C5 n4:271B5E9C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E9D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5EAC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5EAD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5EA7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5EA8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5EAA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5EA9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5EAB-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Helminthic Microorganisms
n3:casRegistryNumber
20559-55-1
n3:category
n3:Bioavailability
n4:271B5EB2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5EB4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5EB5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5EB6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5EB1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5EB0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5EB3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5EA1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5EAE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5EAF-363D-11E5-9242-09173F13E4C5